[Evidence for Antiplatelet Drug Therapy for Moyamoya Disease]

Area of Science:

• Neurology
• Vascular Medicine
• Pharmacology

Background:

• Moyamoya disease (MMD) is a rare cerebrovascular disorder.
• Current research on antiplatelet drugs for MMD primarily consists of small observational studies.
• Randomized clinical trials are lacking to establish definitive stroke prevention strategies in MMD.

Purpose of the Study:

• To review the existing evidence on antiplatelet drug use in Moyamoya disease.
• To explore the potential benefits and risks of antiplatelet therapy for stroke prevention in MMD.
• To highlight the specific properties of cilostazol in managing MMD.

Main Methods:

• Review of retrospective observational and prospective studies.
• Analysis of data regarding antiplatelet drug efficacy and safety in MMD.
• Evaluation of transcranial Doppler ultrasound findings for microembolic signals.

Main Results:

• Antiplatelet drugs have limited effectiveness for ischemic MMD overall.
• Patients with microembolic signals may benefit from antiplatelet therapy to prevent cerebral infarction.
• No data suggests antiplatelet drugs increase hemorrhagic stroke risk in MMD.
• Antiplatelet agents may improve bypass graft patency after surgical intervention.

Conclusions:

• Cilostazol demonstrates clinical benefits in MMD patients due to increased cerebral blood flow and cognitive improvement.
• Further research, including randomized trials, is needed to clarify the role of antiplatelet drugs in MMD stroke prevention.
• Antiplatelet therapy may be considered for specific MMD patient subgroups, particularly those with embolic signals or undergoing bypass surgery.